Purple Biotech (PPBT)
(Delayed Data from NSDQ)
$2.15 USD
-0.11 (-4.87%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $2.26 +0.11 (5.12%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
PPBT 2.15 -0.11(-4.87%)
Will PPBT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PPBT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PPBT
PPBT Stock Surges 150% on Superior Efficacy of PDAC Combo Therapy
What Makes Purple Biotech (PPBT) a New Buy Stock
PPBT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for PPBT
Purple Biotech GAAP EPADS of -$0.57
Purple Biotech Reports Second Quarter 2025 Financial Results | PPBT Stock News
Purple Biotech reports Q2 EPS 40c vs $1.80 last year
Purple Biotech (PPBT) Highlights Scientific Progress and Strategic Goals for 2025 | PPBT Stock News
Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical ...